Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvolusEOLS +1.87%68 Return-on-Tangible-Asset is -27.61% as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 68/100 and a GF Value™ of $13.70 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Evolus ranks worse than 86.41% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Evolus's annualizedNet Income for the quarter that ended in Mar. 2026 was $-42.7 Mil. Evolus's average total tangible assets for the quarter that ended in Mar. 2026 was $154.7 Mil. Therefore, Evolus's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -27.61%.
The historical rank and industry rank for Evolus's Return-on-Tangible-Asset or its related term are showing as below:
EOLS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -949.15 Med: -52.28 Max: -11.92
Current: -28.59
During the past 11 years, Evolus's highest Return-on-Tangible-Asset was -11.92%. The lowest was -949.15%. And the median was -52.28%.
EOLS's Return-on-Tangible-Asset is ranked worse than 86.41% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.155
vs EOLS: -28.59
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Evolus Return-on-Tangible-Asset Related Terms
Evolus Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Evolus's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOLS vs NIKA, EBS, ELTP: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Evolus's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -27.61% mean?
Evolus (EOLS) has a Return-on-Tangible-Asset of -27.61% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #871 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 86.4%.
Is Evolus' Return-on-Tangible-Asset too high?
Evolus' current Return-on-Tangible-Asset is -27.61%. Based on the distribution chart, Evolus ranks #871 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Return-on-Tangible-Asset compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #871 out of 1008 companies for Return-on-Tangible-Asset. This places Evolus in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current Return-on-Tangible-Asset is -27.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.70, compared to a current price of $5.74 — trading 58.1% below its estimated fair value. The current Return-on-Tangible-Asset is -27.61%. Evolus' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Evolus (EOLS), the current Return-on-Tangible-Asset is -27.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $5.74 is trading 58.1% below its estimated GF Value™ of $13.70.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
Return-on-Tangible-Asset: -27.61%
GF Value™: $13.70 vs. price of $5.74 (58.1% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
68GF Score
Get the complete analysis for EOLS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
